Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals reported strong Q3 FY26 results with consolidated revenue from operations rising 13.49% year-on-year to Rs. 166.32 crore, driven by robust demand across cardiac, diabetic, dermatology and ENT segments. Net profit surged 37.70% YoY to Rs. 28.60 crore, while EBITDA grew 18.73% to Rs. 38.74 crore, reflecting healthy margin expansion. For the nine months ended December 2025, revenue grew 6.31% to Rs. 483.75 crore and net profit rose 7.76% to Rs. 76.26 crore. EPS for Q3 stood at Rs. 14.28 versus Rs. 10.37 in Q3 FY25. The company maintains a debt-free balance sheet and is targeting Rs. 1,000 crore revenue over the next three years, supported by 15-18% annual growth ambitions and exports to 60+ countries.
Positive for shareholders — strong double-digit profit growth and EBITDA margin expansion signal healthy operational performance. CRISIL has reaffirmed its A/Stable rating, FII holding is at 4.70%, and the debt-free status combined with ambitious growth targets supports a constructive outlook for the stock.